Maurino, Jorge http://orcid.org/0000-0001-9858-3555
Sotoca, Javier
Sempere, Ángel P.
Brieva, Luis
López de Silanes, Carlos
Caminero, Ana B.
Terzaghi, María
Gracia-Gil, Julia
Saposnik, Gustavo
Funding for this research was provided by:
Roche Spain (ML40361)
Article History
Accepted: 5 September 2020
First Online: 25 September 2020
Declarations
:
: This study was funded by the Medical Department of Roche Farma Spain (ML40361). The funding source had no role in the design, analysis, and interpretation of the data, review or approval of the manuscript, and decision to submit for publication. Ocrelizumab (manufactured by Roche Farma) was not included as a therapeutic option for any of the simulated case scenarios.
: JM is an employee of Roche Farma Spain. GS reports receiving grants and personal fees from Roche Canada and Spain and being supported by the Heart and Stroke Foundation of Canada Scientist Award. JS, APS, LB, CLS, ABC, MT, and JGG declare they have no conflict of interest.
: This study was approved by the institutional review board of the Hospital Universitari Clínic i Provincial de Barcelona (code ML40361).
: Written informed consent to participate in the study was obtained from all subjects.
: Not applicable.
: Not applicable.
: Qualified researchers may request access to individual patient-level data through the clinical study data request platform (ExternalRef removed). Further details on Roche’s criteria for eligible studies are available at ExternalRef removed. For further details on Roche’s Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see ExternalRef removed.
: JM: concept and design, interpretation of data, and drafting the manuscript and revising it for intellectual content. JS: data acquisition, interpretation of data, and revising manuscript for intellectual content. APS: design of the case scenarios, interpretation of data, and revising manuscript for intellectual content. LB, CLS, ABC, and JGG: data acquisition, interpretation of data, and revising manuscript for intellectual content. MT: interpretation of data and revising manuscript for intellectual content. GS: concept and design, statistical analysis, interpretation of data, and drafting the manuscript and revising it for intellectual content.